Accessibility Menu
Harmony Biosciences Stock Quote

Harmony Biosciences (NASDAQ: HRMY)

$29.60
(12.7%)
+3.33
Price as of October 23, 2025, 3:58 p.m. ET

KEY DATA POINTS

Current Price
$29.6
Daily Change
(12.7%) +$3.33
Day's Range
$27.05 - $29.9
Previous Close
$29.6
Open
$27.8
Beta
0.87
Volume
84,353
Average Volume
772,504
Market Cap
1.5B
Market Cap / Employee
$26.27M
52wk Range
$25.52 - $41.61
Revenue
-
Gross Margin
0.75%
Dividend Yield
N/A
EPS
$3.1
CAPs Rating
-
Industry
Pharmaceuticals

The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More

Harmony Biosciences Return vs. S&P

1 Year5 Year5 Year AnnualizedSince IPO
HRMY-24.64%-35.23%-8.32%-29%
S&P+14.5%+93.32%+14.09%+99%

Harmony Biosciences Company Info

Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company, which engages in the development and commercialization of therapies for the treatment of neurological disorders. Its product, WAKIX, is a molecule with a novel mechanism of action designed to increase histamine signaling in the brain by binding to H3 receptors. The company was founded by Jeffrey S. Aronin on July 25, 2017 and is headquartered in Plymouth Meeting, PA.

News & Analysis

Financial Health

General

Q2 2025YOY Change
Revenue$200.49M16.0%
Gross Profit$156.38M16.1%
Gross Margin78.00%0.0%
Market Cap$1.81B5.9%
Market Cap / Employee$6.77M0.0%
Employees2688.9%
Net Income$39.78M243.2%
EBITDA$54.15M97.6%

Currently no data to display

Revenue Growth Rate

Currently no data to display.

Earnings Per Share Growth Rate

Currently no data to display.

Assets

Q2 2025YOY Change
Net Cash$546.05M72.1%
Accounts Receivable$92.98M11.8%
Inventory6.18.1%

Liabilities

Q2 2025YOY Change
Long Term Debt$153.78M-10.7%
Short Term Debt$55.38M17.9%

Ratios

Q2 2025YOY Change
Return On Assets18.40%4.2%
Return On Invested Capital12.93%38.7%

Cash Flow

Q2 2025YOY Change
Free Cash Flow$79.32M88.9%
Operating Free Cash Flow$79.33M86.1%

Valuation

MetricQ3 2024Q4 2024Q1 2025Q2 2025YoY Change
Price to Earnings18.9413.7112.6510.19-34.07%
Price to Book4.223.292.882.52-24.28%
Price to Sales3.412.802.612.39-9.68%
Price to Tangible Book Value5.504.113.472.96-33.67%
Price to Free Cash Flow TTM10.569.168.777.14-12.54%
Enterprise Value to EBITDA31.6128.6826.4027.52-53.10%
Free Cash Flow Yield9.5%10.9%11.4%14.0%14.33%
Return on Equity22.7%25.8%24.7%27.6%22.79%
Total Debt$225.54M$233.15M$207.02M$209.16M-4.61%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.